Butyric Acid

Butyric Acid

SCHEMBL4174319

CCCC(=O)O.CN1CCC[C@@H]1CN(C1CC1)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]ccc3c2c1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.38
KDM4E B2RXH2 5/20 0.35
RXFP1 Q9HBX9 1/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD1 P21728 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR1B P28222 1/20 0.34
OPRM1 P35372 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 3/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4161384 1.00 BRD4 (0.38) BRD4KDM4ERXFP1CHRM2HTR1A
Butyric Acid SCHEMBL4165727 0.87 BRD4 (0.38) BRD4KDM4ERXFP1HTR1AADRA2A
Butyric Acid SCHEMBL4163713 0.87 BRD4 (0.38) BRD4KDM4ERXFP1HTR1AADRA2A
Butyric Acid SCHEMBL4164343 0.87 BRD4 (0.38) BRD4KDM4ERXFP1CHRM2HTR1A
Butyric Acid SCHEMBL4166218 0.84 KDM4E (0.36) BRD4KDM4ERXFP1SLC6A2SLC6A3
Butyric Acid SCHEMBL4155243 0.84 KDM4E (0.39) KDM4ERXFP1SLC6A2SLC6A3LMNA
Butyric Acid SCHEMBL4153181 0.84 KDM4E (0.35) KDM4ERXFP1SLC6A2SLC6A3HSD17B10
Butyric Acid SCHEMBL4155631 0.84 KDM4E (0.35) KDM4ERXFP1SLC6A2SLC6A3HSD17B10
Butyric Acid SCHEMBL4159661 0.83 RXFP1 (0.38) BRD4KDM4ERXFP1SLC6A2HPGD
Butyric Acid SCHEMBL4161016 0.83 RXFP1 (0.38) BRD4KDM4ERXFP1SLC6A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 BRD4 545/4885KDM4E 1970/4885RXFP1 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.